In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications. They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on practice-changing trials and innovative strategies that could shape future treatment landscapes. Studies discussed include: OptimUM-02 phase 2/3 trial for metastatic uveal melanoma ADAM phase 3 trial for MCC5yr update of the phase 2 Keynote 942 trial (adjuvant melanoma)Pilot neoadjuvant studies (NeoReNi, NeoINR)Time of day of infusion and immunotherapy efficacy
No transcript for this episode yet
You can still listen to it in the player. On episodes with a transcript, you can tap any word to see its meaning.
